Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Erin Willert"'
Autor:
Eric T Williams, Roger J. Waltzman, Jack P. Higgins, Asis K. Sarkar, Aimee Iberg, Erin Willert
Publikováno v:
Cancer Research. 80:P1-18
Engineered toxin bodies (ETBs) are differentiated, targeted therapeutics comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of actio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a688f92e5ff9ac875978716924133b4b
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-35
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-35
Autor:
John Newcomb, Wenrou Zheng, Wassilis S. C. Bruins, Niels W.C.J. van de Donk, Erin Willert, Tuna Mutis, Jack P. Higgins, Sonja Zweegman, Ajeeta B Dash
Publikováno v:
Blood. 136:11-12
Monoclonal antibodies (daratumumab, anti-CD38; elotuzumab, anti-SLAMF7) and BCMA-targeting T-cell redirecting therapies are highly effective in a large proportion of multiple myeloma (MM) patients. Nonetheless, age, prior (chemo)therapy, and the tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35962402889839bba74a70ddd4c831af
https://doi.org/10.1182/blood-2020-136928
https://doi.org/10.1182/blood-2020-136928
Autor:
Garrett L. Robinson, Aimee Iberg, Melissa M. Singh, Joseph D. Dekker, Hilario J. Ramos, Jay Zhao, Sara LeMar, Erin Willert
Publikováno v:
Cancer Research. 80:521-521
CD45 is highly expressed on the cell surface of all nucleated hematopoietic cells, including malignant cells of B, T and myeloid lineage. CD45, a receptor tyrosine phosphatase that has important roles in antigen receptor signaling, has multiple isofo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a7bd4e6d818690a927193b29694d2ce
https://doi.org/10.1158/1538-7445.am2020-521
https://doi.org/10.1158/1538-7445.am2020-521
Autor:
Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Aimee Iberg, Asis K. Sarkar, Banmeet Anand, Brigitte Brieschke, Melissa M. Singh, Jack P. Higgins, Jay Zhao, Erin Willert
Publikováno v:
Cancer Research. 80:3366-3366
Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-route through intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d1969a145eabf16102804111c31a3e
https://doi.org/10.1158/1538-7445.am2020-3366
https://doi.org/10.1158/1538-7445.am2020-3366
Autor:
Aimee Iberg, Joseph D. Dekker, Garrett L. Robinson, Edith Acquaye-Seedah, Erin Willert, Hilario J. Ramos, Lilia A. Rabia, Jay Zhao
Publikováno v:
Cancer Research. 80:2278-2278
Tumor resident regulatory T cells (Tregs) are important mediators of an immunosuppressive tumor microenvironment (TME) promoting tumor immune evasion. The presence of Tregs, and a higher ratio of Tregs to effector T cells in the TME, are associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4ac11ff4307e6c0ec0a603d5357a941
https://doi.org/10.1158/1538-7445.am2020-2278
https://doi.org/10.1158/1538-7445.am2020-2278
Autor:
Hilario J. Ramos, Erin Willert, Jay Zhao, Caleigh Howard, Garrett L. Cornelison, Garrett L. Robinson, Aimee Iberg
Publikováno v:
Cancer Research. 80:539-539
Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable of forcing internal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dac11b98460e0c4cd68c3f5bb7a65f4b
https://doi.org/10.1158/1538-7445.am2020-539
https://doi.org/10.1158/1538-7445.am2020-539
Autor:
Roger J. Waltzman, Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Brigitte Brieschke, Garrett L. Cornelison, Aimee T. Iberg, Asis K. Sarkar, Erin Willert, Jay Zhao
Publikováno v:
Journal of Clinical Oncology. 38:12-12
12 Background: Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b661295508d489a702c96aa893aa08e8
https://doi.org/10.1200/jco.2020.38.5_suppl.12
https://doi.org/10.1200/jco.2020.38.5_suppl.12
Autor:
Jack T. Higgins, Roger J. Waltzman, Aimee T. Iberg, Asis K. Sarkar, Eric T Williams, Erin Willert
Publikováno v:
Journal of Clinical Oncology. 38:433-433
433 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered Shiga-like Toxin A subunit genetically fused to antibody-like binding domains. MT-5111 is a de-immunized ETB targeting HER2 for solid tumors. MT-5111 works thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0aa977feff26c733bdd5663bacfd8e2
https://doi.org/10.1200/jco.2020.38.4_suppl.433
https://doi.org/10.1200/jco.2020.38.4_suppl.433
Autor:
Garrett L. Robinson, Erin Willert, Jack P. Higgins, Sangeetha Rajagopalan, Brigitte Brieschke, Jennifer Erdman, William Null
Publikováno v:
Cancer Research. 75:P4-15
The HER2 receptor is overexpressed in 20-30% of breast cancers. HER2 overexpression in breast cancer has been successfully targeted by both antibody and antibody-drug conjugate (ADC) approaches. The recently approved trastuzumab-emtansine (T-DM1, Kad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df97489205e11ca97f35824cc574057c
https://doi.org/10.1158/1538-7445.sabcs14-p4-15-17
https://doi.org/10.1158/1538-7445.sabcs14-p4-15-17
Autor:
Richard Labotka, Yuhong Zhang, Divya Manoharan, Ajeeta B Dash, Erin Willert, Robert F. Cornell, Jack P. Higgins, Roger J. Waltzman, Michael J. Hanley, Jianchang Lin, Alexander Vorog, Ola Landgren, Morgan Leichter, Sikander Ailawadhi, Anya Lublinsky, Sean Ottinger, Shaji Kumar, John Newcomb
Publikováno v:
Blood. 134:1867-1867
Background CD38 is highly expressed on MM cells, hence anti-CD38 agents are of interest as a therapeutic approach in MM. The anti-CD38 monoclonal antibody, dara, as mono- or combination therapy, has substantially improved efficacy outcomes in RRMM, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80089b15cc77544eef05f0f7e4a2a4da
https://doi.org/10.1182/blood-2019-125629
https://doi.org/10.1182/blood-2019-125629